TY - JOUR
T1 - Missense and truncating variants in CHD5 in a dominant neurodevelopmental disorder with intellectual disability, behavioral disturbances, and epilepsy
AU - Parenti, Ilaria
AU - Lehalle, Daphné
AU - Nava, Caroline
AU - Torti, Erin
AU - Leitão, Elsa
AU - Person, Richard
AU - Mizuguchi, Takeshi
AU - Matsumoto, Naomichi
AU - Kato, Mitsuhiro
AU - Nakamura, Kazuyuki
AU - de Man, Stella A.
AU - Cope, Heidi
AU - Shashi, Vandana
AU - Friedman, Jennifer
AU - Joset, Pascal
AU - Steindl, Katharina
AU - Rauch, Anita
AU - Muffels, Irena
AU - van Hasselt, Peter M.
AU - Petit, Florence
AU - Smol, Thomas
AU - Le Guyader, Gwenaël
AU - Bilan, Frédéric
AU - Sorlin, Arthur
AU - Vitobello, Antonio
AU - Philippe, Christophe
AU - van de Laar, Ingrid M.B.H.
AU - van Slegtenhorst, Marjon A.
AU - Campeau, Philippe M.
AU - Au, Ping Yee Billie
AU - Nakashima, Mitsuko
AU - Saitsu, Hirotomo
AU - Yamamoto, Tatsuya
AU - Nomura, Yumiko
AU - Louie, Raymond J.
AU - Lyons, Michael J.
AU - Dobson, Amy
AU - Plomp, Astrid S.
AU - Motazacker, M. Mahdi
AU - Kaiser, Frank J.
AU - Timberlake, Andrew T.
AU - Fuchs, Sabine A.
AU - Depienne, Christel
AU - Mignot, Cyril
AU - Acosta, Maria T.
AU - Adam, Margaret
AU - Adams, David R.
AU - Agrawal, Pankaj B.
AU - Alejandro, Mercedes E.
AU - Alvey, Justin
N1 - Funding Information:
We thank the patients and their family for their participation in this study. The research generating these results was financially supported by Fondation Maladies Rares, Bio-Psy Labex, “Investissements d’avenir” program ANR-10-IAIHU-06 (IHU-A-ICM), the Japan Agency for Medical Research and Development (AMED) (JP20ek0109486, JP20dm0107090, JP20ek0109301, JP20ek0109348, and JP20kk0205012 to N. M.); JSPS KAKENHI (JP17H01539 to N. M. and JP20K08164 to T. M.); Intramural research grants for Neurological and Psychiatric Disorders of NCNP from the Ministry of Health, Labour and Welfare (30-6 and 30-7 to N. M.), the Takeda Science Foundation (to T. M. and N. M.) and the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award Number U01HG007672 (Duke University). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
Open Access funding enabled and organized by Projekt DEAL. The research generating these results was financially supported by Fondation Maladies Rares, Bio-Psy Labex, “Investissements d’avenir” program ANR-10-IAIHU-06 (IHU-A-ICM), the Japan Agency for Medical Research and Development (AMED) (JP20ek0109486, JP20dm0107090, JP20ek0109301, JP20ek0109348, and JP20kk0205012 to N. M.); JSPS KAKENHI (JP17H01539 to N. M. and JP20K08164 to T. M.); Intramural research grants for Neurological and Psychiatric Disorders of NCNP from the Ministry of Health, Labour and Welfare (30-6 and 30-7 to N. M.), the Takeda Science Foundation (to T. M. and N. M.), and the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award Number U01HG007672 (Duke University).
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/7
Y1 - 2021/7
N2 - Located in the critical 1p36 microdeletion region, the chromodomain helicase DNA-binding protein 5 (CHD5) gene encodes a subunit of the nucleosome remodeling and deacetylation (NuRD) complex required for neuronal development. Pathogenic variants in six of nine chromodomain (CHD) genes cause autosomal dominant neurodevelopmental disorders, while CHD5-related disorders are still unknown. Thanks to GeneMatcher and international collaborations, we assembled a cohort of 16 unrelated individuals harboring heterozygous CHD5 variants, all identified by exome sequencing. Twelve patients had de novo CHD5 variants, including ten missense and two splice site variants. Three familial cases had nonsense or missense variants segregating with speech delay, learning disabilities, and/or craniosynostosis. One patient carried a frameshift variant of unknown inheritance due to unavailability of the father. The most common clinical features included language deficits (81%), behavioral symptoms (69%), intellectual disability (64%), epilepsy (62%), and motor delay (56%). Epilepsy types were variable, with West syndrome observed in three patients, generalized tonic–clonic seizures in two, and other subtypes observed in one individual each. Our findings suggest that, in line with other CHD-related disorders, heterozygous CHD5 variants are associated with a variable neurodevelopmental syndrome that includes intellectual disability with speech delay, epilepsy, and behavioral problems as main features.
AB - Located in the critical 1p36 microdeletion region, the chromodomain helicase DNA-binding protein 5 (CHD5) gene encodes a subunit of the nucleosome remodeling and deacetylation (NuRD) complex required for neuronal development. Pathogenic variants in six of nine chromodomain (CHD) genes cause autosomal dominant neurodevelopmental disorders, while CHD5-related disorders are still unknown. Thanks to GeneMatcher and international collaborations, we assembled a cohort of 16 unrelated individuals harboring heterozygous CHD5 variants, all identified by exome sequencing. Twelve patients had de novo CHD5 variants, including ten missense and two splice site variants. Three familial cases had nonsense or missense variants segregating with speech delay, learning disabilities, and/or craniosynostosis. One patient carried a frameshift variant of unknown inheritance due to unavailability of the father. The most common clinical features included language deficits (81%), behavioral symptoms (69%), intellectual disability (64%), epilepsy (62%), and motor delay (56%). Epilepsy types were variable, with West syndrome observed in three patients, generalized tonic–clonic seizures in two, and other subtypes observed in one individual each. Our findings suggest that, in line with other CHD-related disorders, heterozygous CHD5 variants are associated with a variable neurodevelopmental syndrome that includes intellectual disability with speech delay, epilepsy, and behavioral problems as main features.
KW - Adolescent
KW - Catalytic Domain
KW - Child
KW - Child, Preschool
KW - Cohort Studies
KW - DNA Helicases/genetics
KW - Epilepsy/genetics
KW - Female
KW - Genes, Dominant
KW - Humans
KW - Intellectual Disability/genetics
KW - Male
KW - Mutation, Missense
KW - Nerve Tissue Proteins/genetics
KW - Neurodevelopmental Disorders/genetics
KW - Pedigree
KW - Young Adult
UR - http://www.scopus.com/inward/record.url?scp=85108208546&partnerID=8YFLogxK
U2 - 10.1007/s00439-021-02283-2
DO - 10.1007/s00439-021-02283-2
M3 - Article
C2 - 33944996
SN - 0340-6717
VL - 140
SP - 1109
EP - 1120
JO - Human Genetics
JF - Human Genetics
IS - 7
ER -